Navigation Links
Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa
Date:2/8/2013

SAN DIEGO, February 8, 2013 /PRNewswire/ --

Shire plc (LSE: SHP, NASDAQ: SHPG), today announced the initiation of a Phase 3 study designed to evaluate the efficacy and safety of ABH001, its dermal substitute therapy, for the treatment of non-healing wounds in patients with Epidermolysis Bullosa (EB), a group of rare genetic skin disorders that begin to manifest at birth or early childhood and occur in approximately 19 per 1 million live births in the US. [i]  

"People affected by EB suffer skin blisters and almost constant, acute pain and scarring," said the study's Principal Investigator, H. Alan Arbuckle , MD, Section Head Pediatric Dermatology Kaiser Permanente Colorado, Wound Care Consultant, Epidermolysis Bullosa Center of Excellence, The Children's Hospital, Aurora Colorado . "The current standard of care is daily wound care, bandaging and pain management. I am excited to be involved in testing the efficacy and safety of ABH001 as a potential treatment option for these patients."  

ABH001 for EB has been granted an orphan drug designation in the US and EU, and has also received Fast Track designation from the US Food and Drug Administration (FDA), which is aimed at facilitating the development and expediting the review of drugs and biologics that fill an unmet medical need. In addition, the European Medicines Agency's Pediatric Committee has agreed on a pediatric investigation plan for ABH001 for the treatment of EB.

The new Phase 3 study is a multi-site, prospective, randomized, open-label, intra-subject controlled trial evaluating the efficacy and safety of ABH001 to initiate healing and reduce the wound surface area of selected stalled, chronic cutaneous wounds associated with generalized EB. Approximately 20 subjects with generalized EB age
'/>"/>

SOURCE Shire plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Shire to Acquire FerroKin BioSciences, Inc., and its Phase 2 Iron Chelator Treatment
2. Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders
3. Shire plc: First Quarter 2012 Results Date Notification - April 26, 2012
4. Shire Facebook Page Increases Awareness of Hereditary Angioedema (HAE) in Support of First HAE Awareness Day May 16th
5. Berkshire Corporation Offers Live Chat For Americas Website and Shopping Cart
6. Shire Changes its NASDAQ Ticker Symbol to SHPG
7. Dr. Jeff Jonas Appointed President of Shire Regenerative Medicine Business and Joins Shire Leadership Team
8. Shire and Boston Childrens Hospital Enter Into Broad Research Collaboration
9. Shire Reaches Agreement in Principle With U.S. Government
10. Palm Beach Residents to Learn How the Future of Regenerative Medicine Will Combat Aging
11. ODT Forum Presents Regenerative Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)...  Bill Jacobs Automotive, a group of car dealerships headquartered in ... Heartland Blood Center and offering free oil change coupons for ... Saturday, Jan. 18 at the Bill Jacobs Cadillac and Chevrolet ... http://photos.prnewswire.com/prnh/20140115/MN46637 )  The Bill Jacobs Auto ...
(Date:1/15/2014)... OXFORD, England and SAN JOSE, California ... an international biotechnology company developing antibody-drug conjugates for cancer, today ... its Board of Directors. Dr Reynolds has over 20 years, ... Chief Medical Officer at Seattle Genetics. "I am ...
(Date:1/15/2014)... 2014 Two champions of science, technology, ... of an annual competition for middle and high school ... innovative STEM study. The competition presents students with real-world ... Engineering Aptitude, Mathematics, and Sciences is a program ...
(Date:1/15/2014)... AudioNotch is the internet's leading provider ... treatment of tinnitus. Patients listen to sound therapy that ... period of weeks to months, their tinnitus volume decreases. , ... Notched Music and Notched White Noise. Now, AudioNotch is pleased ...
Breaking Biology Technology:Join the Bill Jacobs Auto blood drive and receive a free oil change 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5
... 2009 Earnings Guidance and Introduces Q1 2009 Guidance FRAZER, ... . (Nasdaq: CEPH ) today reported 2008 ... billion for 2007, exceeding the company,s previously issued guidance. ... year 2008 was $3.27. Excluding amortization expense and ...
... VOLC ), a leader in the development, ... of coronary and peripheral artery,disease, said today that it ... Growth Stock Conference on Wednesday, February 18. , ... and chief executive,officer, will begin at 9:30 a.m., Pacific ...
... Calif., Feb. 12 iZumi Bio, Inc., announced,today the ... and a,member of the company,s Board of Directors. ... Inc. which merged with Transcept Pharmaceuticals,Inc. in January 2009. ... , iZumi Bio is focused ...
Cached Biology Technology:Cephalon's New Product Launches Pace Record 2008 Sales 2Cephalon's New Product Launches Pace Record 2008 Sales 3Cephalon's New Product Launches Pace Record 2008 Sales 4Cephalon's New Product Launches Pace Record 2008 Sales 5Cephalon's New Product Launches Pace Record 2008 Sales 6Cephalon's New Product Launches Pace Record 2008 Sales 7Cephalon's New Product Launches Pace Record 2008 Sales 8Cephalon's New Product Launches Pace Record 2008 Sales 9Cephalon's New Product Launches Pace Record 2008 Sales 10Cephalon's New Product Launches Pace Record 2008 Sales 11Cephalon's New Product Launches Pace Record 2008 Sales 12Cephalon's New Product Launches Pace Record 2008 Sales 13Cephalon's New Product Launches Pace Record 2008 Sales 14Cephalon's New Product Launches Pace Record 2008 Sales 15Cephalon's New Product Launches Pace Record 2008 Sales 16Cephalon's New Product Launches Pace Record 2008 Sales 17Cephalon's New Product Launches Pace Record 2008 Sales 18Cephalon's New Product Launches Pace Record 2008 Sales 19Cephalon's New Product Launches Pace Record 2008 Sales 20Cephalon's New Product Launches Pace Record 2008 Sales 21Volcano Corporation Presentation at Roth Capital Partners Conference to Be Webcast 2iZumi Bio, Inc., Appoints John Walker as Chief Executive Officer 2
(Date:4/23/2014)... (Apr. 23, 2014) People who have had a ... restore neurological function. However, a study conducted in Taiwan, ... Cell Transplantation , but is currently freely available ... , has found that when one group of stroke ... injected directly into the brain and a similar group ...
(Date:4/23/2014)... energy landscape in the U.S., but in some ... energy industry, residents and agricultural interests over already-scarce ... water quality is a potential risk unless there ... the ACS journal Environmental Science & Technology ... out that a major criticism of extracting shale ...
(Date:4/23/2014)... cli-fi, is a newly coined term for novels and films ... from University of Copenhagen shows how these fictions serve as ... consequences of climate change and imagine other living conditions. ... changes in the atmosphere; it is also a cultural phenomenon ... read and the films we see. And there are so ...
Breaking Biology News(10 mins):Autologous stem cell therapy improves motor function in chronic stroke victims 2How to avoid water wars between 'fracking' industry and residents 2Fiction prepares us for a world changed by global warming 2Fiction prepares us for a world changed by global warming 3
... Researchers at the Swedish medical university Karolinska Institutet (KI) have ... parietal parts, to increase the understanding of the capacity of ... in the brain interact. One of the findings they have ... brain,s neuronal network that restricts the number of items we ...
... may one day help people who are not responding ... The Journal of Immunology . Scientists looking at ... to reduce the virus levels in the blood to ... called D-1mT alongside Anti-Retroviral Therapy (ART). Simian Immunodeficiency ...
... that its latest journal, Disease Models & Mechanisms ... MEDLINE. MEDLINE (http://www.pubmed.gov) is the premier bibliographic database of ... National Institutes of Health (NIH), MEDLINE contains over 16 million ... DMM has been recommended for inclusion by ...
Cached Biology News:Computer simulations explain the limitations of working memory 2Potential new HIV drug may help patients not responding to treatment 2Potential new HIV drug may help patients not responding to treatment 3Disease Models & Mechanisms -- selected for indexing in Medline 2
Mouse monoclonal [H4B4] to LAMP2 - Lysosome Marker (Phycoerythrin) ( Abpromise for all tested applications). entrezGeneID: 3920 SwissProtID: P13473...
... Nikon's NIS-Elements revolutionizes imaging software for ... intelligence to microscopes, cameras, components and ... and achiving tools. Its intuitive interface ... acquisition times while providing powerful features ...
AVOID FREEZE/THAW CYCLES. Recognizes the ~32 kDa DNase IIα chain and the ~40 kDa proenzyme. DNase II causes both DNA condensation and DNA fragmentation. ...
Vented Caps for 75 cm2 Flasks...
Biology Products: